Sackler Institute of Pulmonary Pharmacology
To further our understanding of the pathogenesis and treatment of lung disease
The Institute was established in 1993 to provide multidisciplinary research to investigate the mechanisms and pharmacological basis of respiratory diseases. The Sackler Institute is part of the Institute of Pharmaceutical Science and the Department of Pharmacology & Therapeutics (Teaching).
Current Research Activity
The majority of our funding is from the Pharmaceutical Industry, although we have received funds from the Wellcome Trust, MRC, BBSRC, Asthma UK, DSTL, and NERC. The latter funding was awarded as a part of the Biofouling initiative and the work undertaken with this funding (jointly with Dr C Bavington of the Scottish Association for Marine Sciences, Oban and Prof. N. Richardson of the Interdisciplinary Surface Science Laboratory in the University of St. Andrews) has led to the identification of novel sugar molecules with anti-inflammatory properties. Our work has also been central to the discovery and development of a novel inhaled bifunctional of dry (RPL554) having both bronchodilator and antiinflamatory actions in a single molecule. (http://www.kcl.ac.uk/newsevents/news/newsrecords/2013/10-October/New-class-of-drug-shows-promise-for-treating-asthma-and-COPD.aspx)
We have a number of joint grants and research studentships with the Drug Delivery Research Group based in IPS partially investigating the safety of inhaled medicines. In particular we are part of an NC3Rs funded initiative looking at the impact of inhaled medicines on 'foamy macrophages'. (http://www.kcl.ac.uk/lsm/research/divisions/ips/research/drugdelivery/index.aspx)
Studentships from 1993-2018
The Sackler Institute of Pulmonary Pharmacology is also dedicated to the support and training of postgraduate students. Since 1993, we have trained 39 postgraduate students.
Our total funding generated within the Sackler Institute of Pulmonary Pharmacology (1993-2018) is over £13 million.